CH574742A5 - - Google Patents

Info

Publication number
CH574742A5
CH574742A5 CH1062271A CH1062271A CH574742A5 CH 574742 A5 CH574742 A5 CH 574742A5 CH 1062271 A CH1062271 A CH 1062271A CH 1062271 A CH1062271 A CH 1062271A CH 574742 A5 CH574742 A5 CH 574742A5
Authority
CH
Switzerland
Application number
CH1062271A
Inventor
Zaffaroni Alejandro
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from ZA714095A external-priority patent/ZA714095B/xx
Application filed by Alza Corp filed Critical Alza Corp
Publication of CH574742A5 publication Critical patent/CH574742A5/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61D—VETERINARY INSTRUMENTS, IMPLEMENTS, TOOLS, OR METHODS
    • A61D7/00—Devices or methods for introducing solid, liquid, or gaseous remedies or other materials into or onto the bodies of animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
    • A61F9/0017—Introducing ophthalmic products into the ocular cavity or retaining products therein implantable in, or in contact with, the eye, e.g. ocular inserts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A61K9/0039—Devices retained in the uterus for a prolonged period, e.g. intrauterine devices for contraception
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0092—Hollow drug-filled fibres, tubes of the core-shell type, coated fibres, coated rods, microtubules or nanotubes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42—Use of materials characterised by their function or physical properties
    • A61L15/58—Adhesives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
    • A61M31/002—Devices for releasing a drug at a continuous and controlled rate for a prolonged period of time
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Reproductive Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Anesthesiology (AREA)
  • Dermatology (AREA)
  • Medical Informatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Nanotechnology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Materials Engineering (AREA)
  • Medicinal Preparation (AREA)
CH1062271A 1969-04-01 1971-07-19 CH574742A5 (enExample)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US81211669A 1969-04-01 1969-04-01
US00042786A US3854480A (en) 1969-04-01 1970-06-02 Drug-delivery system
ZA714095A ZA714095B (en) 1969-04-01 1971-06-22 Bandage for administering drugs
FR7123703A FR2143564A1 (en) 1969-04-01 1971-06-29 Impregnated bandage - for long term administration of pharmacologically active materials at controlled rates

Publications (1)

Publication Number Publication Date
CH574742A5 true CH574742A5 (enExample) 1976-04-30

Family

ID=37734020

Family Applications (1)

Application Number Title Priority Date Filing Date
CH1062271A CH574742A5 (enExample) 1969-04-01 1971-07-19

Country Status (4)

Country Link
US (1) US3854480A (enExample)
CH (1) CH574742A5 (enExample)
DE (1) DE2135533C3 (enExample)
FR (1) FR2143564A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0144486A3 (en) * 1983-04-27 1986-05-14 Lohmann Gmbh & Co Kg Controlled-release drugsystem and process for preparing it
AT395815B (de) * 1981-06-29 1993-03-25 Alza Corp Therapeutisches abgabesystem zur verabreichung eines wirkstoffes durch die haut

Families Citing this family (614)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4069307A (en) * 1970-10-01 1978-01-17 Alza Corporation Drug-delivery device comprising certain polymeric materials for controlled release of drug
US4016251A (en) * 1972-08-17 1977-04-05 Alza Corporation Vaginal drug dispensing device
US4188951A (en) * 1972-08-17 1980-02-19 Alza Corporation Intrauterine system embracing selected copolymeric membranes for administering beneficial agent
US4177256A (en) * 1973-04-25 1979-12-04 Alza Corporation Osmotic bursting drug delivery device
US4014987A (en) * 1974-06-04 1977-03-29 Alza Corporation Device for delivery of useful agent
US3926188A (en) * 1974-11-14 1975-12-16 Alza Corp Laminated drug dispenser
US4052505A (en) * 1975-05-30 1977-10-04 Alza Corporation Ocular therapeutic system manufactured from copolymer
US4144317A (en) * 1975-05-30 1979-03-13 Alza Corporation Device consisting of copolymer having acetoxy groups for delivering drugs
US4057619A (en) * 1975-06-30 1977-11-08 Alza Corporation Ocular therapeutic system with selected membranes for administering ophthalmic drug
US4186745A (en) * 1976-07-30 1980-02-05 Kauzlarich James J Porous catheters
DE2650306A1 (de) * 1976-11-02 1978-05-03 Merck Patent Gmbh Antibakteriell wirkender wundverband und verfahren zu seiner herstellung
US4164560A (en) * 1977-01-05 1979-08-14 Folkman Moses J Systems for the controlled release of macromolecules
US4391797A (en) * 1977-01-05 1983-07-05 The Children's Hospital Medical Center Systems for the controlled release of macromolecules
US4460367A (en) * 1977-06-09 1984-07-17 Alza Corporation Device containing biocide producing paraformalde and an acid
US4201211A (en) * 1977-07-12 1980-05-06 Alza Corporation Therapeutic system for administering clonidine transdermally
US4190642A (en) * 1978-04-17 1980-02-26 Alza Corporation Ocular therapeutic system for dispensing a medication formulation
EP0009517A1 (en) * 1978-10-04 1980-04-16 THE PROCTER & GAMBLE COMPANY Vaginal contraceptive
US4215691A (en) * 1978-10-11 1980-08-05 Alza Corporation Vaginal contraceptive system made from block copolymer
DE2953373A1 (en) * 1978-12-06 1981-01-08 P Svedman Device for treating tissues,for example skin
US4237888A (en) * 1979-03-23 1980-12-09 The Upjohn Company Two-membrane medicated device for rate-controlled administration of prostaglandins
DE3068649D1 (en) * 1979-03-23 1984-08-30 Upjohn Co Medicated device for controlled drug release
US4308867A (en) * 1979-03-23 1982-01-05 Roseman Theodore J Two-member medicated device for rate-controlled administration of lipophilic pharmaceuticals
EP0021504B1 (en) * 1979-06-25 1984-10-03 THE PROCTER & GAMBLE COMPANY Article for use as catheter or the like
US4392848A (en) * 1979-06-25 1983-07-12 The Procter & Gamble Company Catheterization
US4479795A (en) * 1979-06-29 1984-10-30 The Procter & Gamble Company Antimicrobial polymer compositions
US4343788A (en) * 1979-06-29 1982-08-10 The Procter & Gamble Company Antimicrobial polymer compositions
PL124267B1 (en) * 1979-09-12 1983-01-31 Lilly Co Eli Device for use in the masseter/galea part of a ruminant's gaster
US4326510A (en) * 1979-11-20 1982-04-27 World Health Organization Barrier contraceptive torus
JPS5777617A (en) * 1980-10-20 1982-05-15 Nichiban Co Ltd Plaster for cardiac disease
DE3040978A1 (de) * 1980-10-28 1982-05-27 Schering Ag, 1000 Berlin Und 4619 Bergkamen Vaginalring
FR2512651B1 (fr) * 1981-06-24 1986-01-17 Pere Lahaille Jeanne Produits anti-rides
US4985017A (en) * 1981-07-13 1991-01-15 Alza Corporation Parenteral therapeutical system comprising drug cell
USRE34365E (en) * 1981-07-13 1993-08-31 Intravenous system for delivering a beneficial agent
US4857052A (en) * 1981-07-13 1989-08-15 Alza Corporation Intravenous system for delivering a beneficial agent
US4973307A (en) * 1981-07-13 1990-11-27 Alza Corporation Method for administering drugs to a patient
US4511353A (en) * 1981-07-13 1985-04-16 Alza Corporation Intravenous system for delivering a beneficial agent
US4740198A (en) * 1981-10-09 1988-04-26 Alza Corporation Method of administering intravenous drug using rate-controlled dosage form
US4740201A (en) * 1981-10-09 1988-04-26 Alza Corporation Intravenous system for delivering a beneficial agent
US4432756A (en) * 1981-11-27 1984-02-21 Alza Corporation Parenteral controlled therapy
US5069671A (en) * 1981-07-13 1991-12-03 Alza Corporation Intravenous medication
US4994031A (en) * 1981-07-13 1991-02-19 Alza Corporation Intravenous system for delivering a beneficial agent
US4790820A (en) * 1981-07-13 1988-12-13 Alza Corporation Parenteral agent dispensing equipment with drug releasing member
US4525162A (en) * 1981-07-31 1985-06-25 Alza Corporation Parenteral controlled delivery
US4871360A (en) * 1981-07-31 1989-10-03 Alza Corporation System for intravenous delivery of a beneficial drug at a regulated rates
US4741735A (en) * 1981-10-09 1988-05-03 Alza Corporation Intravenous system for delivering a beneficial agent
US4741734A (en) * 1981-10-09 1988-05-03 Alza Corporation Releasing means for adding agent using releasing means to IV fluid
US4740199A (en) * 1981-10-09 1988-04-26 Alza Corporation Intravenous system for delivering a beneficial agent
US4740200A (en) * 1981-10-09 1988-04-26 Alza Corporation Intravenous system for delivering a beneficial agent
US4740197A (en) * 1981-10-09 1988-04-26 Alza Corporation Intravenous system for delivering a beneficial agent via polymer delivery
US4586922A (en) * 1981-10-09 1986-05-06 Alza Corporation Intravenous system for delivering a beneficial agent
US4740103A (en) * 1981-10-09 1988-04-26 Alza Corporation Intravenous system for delivering a beneficial agent
US4493702A (en) * 1981-11-27 1985-01-15 Alza Corporation Parenteral administration using osmotically motivated delivery system
US4583981A (en) * 1981-11-27 1986-04-22 Alza Corporation Parenteral controlled therapy, using a porous matrix with parenteral agent
US4484909A (en) * 1981-11-27 1984-11-27 Alza Corporation Parenteral therapy using solid drug
US4579553A (en) * 1981-11-27 1986-04-01 Alza Corporation Parenteral controlled therapy
US4548599A (en) * 1981-11-27 1985-10-22 Alza Corporation Parenteral controlled therapy
US4479793A (en) * 1981-11-27 1984-10-30 Alza Corporation Parenteral administration using drug delivery device
US4479794A (en) * 1981-11-27 1984-10-30 Alza Corporation System for intravenous therapy
US4552556A (en) * 1981-11-27 1985-11-12 Alza Corporation Parenteral controlled therapy
US4664650A (en) * 1982-05-24 1987-05-12 Alza Corporation Apparatus for parenteral infusion of fluid containing beneficial agent
US4515585A (en) * 1982-05-24 1985-05-07 Alza Corporation System for parenteral administration of agent
US4908019A (en) * 1982-05-24 1990-03-13 Alza Corporation Apparatus comprising dual reservoirs for parenteral infusion of fluid containing beneficial agent
US4709996A (en) * 1982-09-30 1987-12-01 Michelson Paul E Fluid lens
CA1206049A (en) * 1982-09-30 1986-06-17 Paul E. Michelson Osmotic device for physiological applications
FR2534140B1 (fr) * 1982-10-12 1986-01-31 Fournier Laboratoires Nouveau dispositif pour l'administration percutanee de medicaments
US4613330A (en) * 1982-11-26 1986-09-23 Michelson Paul E Delivery system for desired agents
FR2538247B1 (fr) * 1982-12-23 1986-05-23 Pere Lahaille Jeanne Pastille anti-rides et/ou traitant la peau
US4469671A (en) * 1983-02-22 1984-09-04 Eli Lilly And Company Contraceptive device
DE3306250A1 (de) * 1983-02-23 1984-08-23 Basf Ag, 6700 Ludwigshafen Sphaerische einkristalle fuer pharmazeutische zwecke
DE3315272C2 (de) * 1983-04-27 1986-03-27 Lohmann Gmbh & Co Kg, 5450 Neuwied Pharmazeutisches Produkt und Verfahren zu seiner Herstellung
US4564364A (en) * 1983-05-26 1986-01-14 Alza Corporation Active agent dispenser
FR2548021B1 (fr) * 1983-06-29 1986-02-28 Dick P R Compositions pharmaceutiques dermiques a action prolongee et continue a base d'acides gras essentiels
DE3333240A1 (de) * 1983-09-12 1985-03-28 Schering AG, 1000 Berlin und 4709 Bergkamen Mittel zur transdermalen applikation von arzneimittelwirkstoffen
US4563184A (en) * 1983-10-17 1986-01-07 Bernard Korol Synthetic resin wound dressing and method of treatment using same
US4623329A (en) * 1983-12-15 1986-11-18 The Procter & Gamble Company Drainage and infusion catheters having a capillary sleeve forming a reservoir for a fluid antimicrobial agent
DE3582439D1 (de) * 1984-01-28 1991-05-16 Roshdy Ismail Mittel zur behandlung von herzerkrankungen.
DE3505536C2 (de) * 1984-03-07 1994-08-04 Holz Wolfgang Verfahren und Arzneimittelbehälter zur Verarbreichung von Medikamenten o.dgl. an in Wasserbehältern gehaltene Tiere, insbesondere Fische
US4596555A (en) * 1984-05-14 1986-06-24 Alza Corporation Parenteral delivery system utilizing a hollow fiber cellular unit
US4511351A (en) * 1984-05-14 1985-04-16 Alza Corporation Parenteral delivery system utilizing a hollow fiber cellular unit
US4511352A (en) * 1984-05-14 1985-04-16 Alza Corporation Parenteral delivery system with in-line container
US4618487A (en) * 1984-07-06 1986-10-21 Alza Corporation Device for administering calcium ascorbate
DE3447833A1 (de) * 1984-12-29 1986-07-10 Allan Gerhard 8047 Karlsfeld Frühauf Tuch o.dgl. mit einen wirkstoff enthaltenden mikrokapseln
US4685918A (en) * 1985-02-01 1987-08-11 Merck & Co., Inc. Lipid osmotic pump
US4720384A (en) * 1985-05-03 1988-01-19 E. I. Du Pont De Nemours And Company Manufacture of hollow fine tubular drug delivery systems
US4673565A (en) * 1985-05-03 1987-06-16 E. I. Du Pont De Nemours And Company Pharmaceutical compositions containing hollow fine tubular drug delivery systems
US4645502A (en) * 1985-05-03 1987-02-24 Alza Corporation Transdermal delivery of highly ionized fat insoluble drugs
US4666441A (en) * 1985-12-17 1987-05-19 Ciba-Geigy Corporation Multicompartmentalized transdermal patches
US4797284A (en) * 1986-03-12 1989-01-10 Merck & Co., Inc. Transdermal drug delivery system
US4762717A (en) * 1986-03-21 1988-08-09 The General Hospital Corporation Continuous delivery of luteinizing hormone releasing hormone compositions in combination with sex steroid delivery for use as a contraceptive
US4959217A (en) * 1986-05-22 1990-09-25 Syntex (U.S.A.) Inc. Delayed/sustained release of macromolecules
US5286494A (en) * 1986-07-02 1994-02-15 Schering Aktiengesellschaft Medicinal agents with sustained action
US6117448A (en) * 1986-08-28 2000-09-12 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg Transdermal therapeutic system, its use and production process
US6110488A (en) * 1986-08-28 2000-08-29 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg Transdermal therapeutic system, its use and production process
US5820876A (en) 1986-08-28 1998-10-13 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg Transdermal therapeutic system
US6139868A (en) * 1986-08-28 2000-10-31 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg Transdermal therapeutic system, its use and production process
DE3629304A1 (de) * 1986-08-28 1988-03-24 Lohmann Gmbh & Co Kg Transdermales therapeutisches system, seine verwendung und verfahren zu seiner herstellung
US6126963A (en) 1986-08-28 2000-10-03 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg Transdermal therapeutic system, its use and production process
JPH0794384B2 (ja) * 1986-09-01 1995-10-11 帝国製薬株式会社 徐放性口腔内用製剤
DE3750085T2 (de) * 1987-01-09 1994-09-22 Hercon Lab Wasserdampf durchlässiger Verband.
US5322695A (en) * 1987-01-09 1994-06-21 Hercon Laboratories Corporation Moisture-vapor-permeable dressing
US4894231A (en) * 1987-07-28 1990-01-16 Biomeasure, Inc. Therapeutic agent delivery system
US4996060A (en) * 1988-03-25 1991-02-26 Alza Corporation Device comprising liner for protecting fluid sensitive medicament
US4855141A (en) * 1988-03-25 1989-08-08 Alza Corporation Device comprising means for protecting and dispensing fluid sensitive medicament
US4959218A (en) * 1988-03-25 1990-09-25 Alza Corporation Method for delivering somatotropin to an animal
US4942037A (en) * 1988-06-02 1990-07-17 Merck & Co., Inc. Transdermal delivery systems
DE3823070A1 (de) * 1988-07-07 1990-02-22 Kettelhack Riker Pharma Gmbh Selbstklebendes heftpflaster
US5135523A (en) * 1988-12-13 1992-08-04 Alza Corporation Delivery system for administering agent to ruminants and swine
US5037420A (en) * 1988-12-13 1991-08-06 Alza Corporation Delivery system comprising two sections for delivering somatotropin
US5110596A (en) * 1988-12-13 1992-05-05 Alza Corporation Delivery system comprising means for delivering agent to livestock
US5057318A (en) * 1988-12-13 1991-10-15 Alza Corporation Delivery system for beneficial agent over a broad range of rates
US5174999A (en) * 1988-12-13 1992-12-29 Alza Corporation Delivery system comprising fluid ingress and drug egress
US5034229A (en) * 1988-12-13 1991-07-23 Alza Corporation Dispenser for increasing feed conversion of hog
US5059423A (en) * 1988-12-13 1991-10-22 Alza Corporation Delivery system comprising biocompatible beneficial agent formulation
DE3844247A1 (de) * 1988-12-29 1990-07-12 Minnesota Mining & Mfg Vorrichtung, insbesondere pflaster zum transdermalen verabreichen eines medikaments
US5053227A (en) * 1989-03-22 1991-10-01 Cygnus Therapeutic Systems Skin permeation enhancer compositions, and methods and transdermal systems associated therewith
US5059426A (en) * 1989-03-22 1991-10-22 Cygnus Therapeutic Systems Skin permeation enhancer compositions, and methods and transdermal systems associated therewith
US4973468A (en) * 1989-03-22 1990-11-27 Cygnus Research Corporation Skin permeation enhancer compositions
FR2648143B1 (fr) * 1989-06-08 1991-09-06 Rhone Poulenc Chimie Composition comprenant un copolymere silicone thermoplastique et un compose de l'iode, utilisable apres sa mise en forme, pour le traitement des eaux
US5776493A (en) * 1989-07-14 1998-07-07 Alza Corporation Oral osmotic device for delivery of nystatin with hydrogel driving member
US5091186A (en) * 1989-08-15 1992-02-25 Cygnus Therapeutic Systems Biphasic transdermal drug delivery device
US5124157A (en) 1989-08-18 1992-06-23 Cygnus Therapeutic Systems Method and device for administering dexmedetomidine transdermally
US5295984A (en) 1989-12-07 1994-03-22 Ultrafem, Inc. Vaginal discharge collection device and intravaginal drug delivery system
US6264638B1 (en) 1989-12-07 2001-07-24 Ultrafem, Inc. Intravaginal drug delivery system and discharge collection device
US5417671A (en) * 1990-05-23 1995-05-23 Jackson; Richard R. Medical devices having local anesthetic effect and methods of their manufacture
DE69125855T2 (de) * 1990-06-01 1997-07-31 The Population Council, New York, N.Y. Therapeutisch wirksame, örtliche anwendung von st1435
US5238687A (en) * 1990-07-11 1993-08-24 Alza Corporation Delivery device with a protective sleeve
US5180591A (en) * 1990-07-11 1993-01-19 Alza Corporation Delivery device with a protective sleeve
US5234693A (en) * 1990-07-11 1993-08-10 Alza Corporation Delivery device with a protective sleeve
US5234692A (en) * 1990-07-11 1993-08-10 Alza Corporation Delivery device with a protective sleeve
US5234694A (en) * 1990-07-11 1993-08-10 Alza Corporation Method for increasing feed efficiency in animals
DE59203307D1 (de) 1991-06-10 1995-09-21 Lohmann Therapie Syst Lts Nitroglycerin-pflaster und verfahren zu seiner herstellung.
US5407686A (en) * 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient
US5248310A (en) * 1992-03-27 1993-09-28 Alza Corporation Oral osmotic device with hydrogel driving member
US5512299A (en) * 1992-03-30 1996-04-30 Alza Corporation Method of treating oral inflammatory disease
US5827245A (en) * 1992-07-16 1998-10-27 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg Transdermal therapeutic system comprising the active subtance 17-β-Estradiol (Anhydrous)
DE4223360C1 (enExample) * 1992-07-16 1993-04-08 Lts Lohmann Therapie-Systeme Gmbh & Co Kg, 5450 Neuwied, De
US5573776A (en) * 1992-12-02 1996-11-12 Alza Corporation Oral osmotic device with hydrogel driving member
US5358721A (en) * 1992-12-04 1994-10-25 Alza Corporation Antiviral therapy
DE4328217C2 (de) * 1993-08-21 1996-01-11 Lohmann Therapie Syst Lts Therapeutisches System zur Behandlung der Psoriasis
AU1086795A (en) * 1993-11-03 1995-05-23 Clarion Pharmaceuticals, Inc. Hemostatic patch
US5762955A (en) 1994-02-04 1998-06-09 Smith; Stephen Jay Method for application and maintenance of medication on body tissue
US5660848A (en) * 1994-11-02 1997-08-26 The Population Council, Center For Biomedical Research Subdermally implantable device
US5531681A (en) * 1995-01-13 1996-07-02 Abbott Laboratories Apparatus for altering composition of nutritional product during enteral tube feeding
TW592729B (en) * 1995-04-06 2004-06-21 Janssen Pharmaceutica Nv Rate-controlled transdermal administration of risperidone
US5965532A (en) * 1996-06-28 1999-10-12 Trustees Of Tufts College Multivalent compounds for crosslinking receptors and uses thereof
BR9715048A (pt) 1996-07-03 2001-01-16 Ultrafem Inc Método e sistema para a manufatura de artigos elastoméricos
US6007837A (en) * 1996-07-03 1999-12-28 Alza Corporation Drug delivery devices and process of manufacture
US20030093143A1 (en) * 1999-03-01 2003-05-15 Yiju Zhao Medical device having surface depressions containing nitric oxide releasing compound
US5824657A (en) * 1997-03-18 1998-10-20 Cubist Pharmaceuticals, Inc. Aminoacyl sulfamides for the treatment of hyperproliferative disorders
WO1998043630A1 (en) 1997-04-02 1998-10-08 Brigham And Women's Hospital, Inc. Means of ascertaining an individual's risk profile for atherosclerotic disease
US6174545B1 (en) 1997-07-01 2001-01-16 Alza Corporation Drug delivery devices and process of manufacture
DE69932717T2 (de) 1998-05-22 2007-08-09 Ottawa Health Research Institute, Ottawa Methoden und produkte zur induzierung mukosaler immunität
US6117441A (en) * 1998-07-02 2000-09-12 The Population Council, Inc. Silicone core long term androgen delivery implant
EP1096952B1 (en) 1998-07-15 2008-05-21 The Brigham And Women's Hospital, Inc. Polysaccharide vaccine for staphylococcal infections
US6117442A (en) * 1998-11-12 2000-09-12 Leiras Oy Drug delivery device, especially for the delivery of androgens
US6056976A (en) * 1998-11-12 2000-05-02 Leiras Oy Elastomer, its preparation and use
US6063395A (en) * 1998-11-12 2000-05-16 Leiras Oy Drug delivery device especially for the delivery of progestins and estrogens
HK1041009B (en) 1998-12-30 2009-05-08 Beth Israel Deaconess Medical Center, Inc. Characterization of the soc/crac calcium channel protein family
DE19912477A1 (de) * 1999-03-19 2000-09-28 Lohmann Therapie Syst Lts Transdermales therapeutisches System und Verfahren zu seiner Herstellung
US6217895B1 (en) * 1999-03-22 2001-04-17 Control Delivery Systems Method for treating and/or preventing retinal diseases with sustained release corticosteroids
CA2372176A1 (en) 1999-05-05 2000-11-09 Merck & Co., Inc. Novel prolines as antimicrobial agents
EP1176958B1 (en) 1999-05-05 2004-07-28 Merck & Co., Inc. Novel catechols as antimicrobial agents
US6251432B1 (en) 1999-07-01 2001-06-26 Abbott Laboratories Sustained release dosage form unit having latex coating and method of making the same
JP4428899B2 (ja) 1999-07-02 2010-03-10 エルテーエス ローマン テラピー−ジステーメ アーゲー ポリシロキサンおよび両親和性溶媒を基にした微小貯蔵所系
EP2267029B1 (en) 1999-09-03 2016-06-15 The Brigham And Women's Hospital, Inc. Methods and compositions for treatment of inflammatory disease using Cadherin-11 modulating agents
EP1225901A2 (en) * 1999-09-21 2002-07-31 Emory University Uses and compositions for treating platelet-related disorders using anagrelide
DE19949202A1 (de) * 1999-10-13 2001-05-03 Lohmann Therapie Syst Lts Transdermales therapeutisches System zur Abgabe von Acetylsalicylsäure und/oder Salicylsäure
DE19949252B4 (de) * 1999-10-13 2004-02-12 Lts Lohmann Therapie-Systeme Ag Verwendung eines superfiziellen therapeutischen Systems zur topischen Applikation von Acetylsalicylsäure zur Behandlung von Akne-Erkrankungen und Verfahren zu seiner Herstellung
EP2298790A1 (en) 1999-12-15 2011-03-23 Cubist Pharmaceuticals, Inc. Daptomycin analogs as antibacterial agents
US6476079B1 (en) * 1999-12-23 2002-11-05 Leiras Oy Devices for the delivery of drugs having antiprogestinic properties
US6696412B1 (en) 2000-01-20 2004-02-24 Cubist Pharmaceuticals, Inc. High purity lipopeptides, Lipopeptide micelles and processes for preparing same
CA2402160C (en) 2000-03-08 2012-02-14 Massachusetts Institute Of Technology Heparinase iii and uses thereof
CA2404858A1 (en) * 2000-04-12 2001-10-25 Minerva Biotechnologies Corporation Treatment of neurodegenerative disease
US20040115268A1 (en) * 2000-04-26 2004-06-17 Control Delivery Systems, Inc. Systemic delivery of antiviral agents
US6375972B1 (en) 2000-04-26 2002-04-23 Control Delivery Systems, Inc. Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof
SI1296714T1 (sl) 2000-06-22 2010-01-29 S For Entpr University Of Iowa Kombinacija CpG-ja in protiteles, usmerjenih proti CD19, CD20, CD22 ali CD40 za zdravljenje ali preprečevanje raka
AU2001281250A1 (en) 2000-08-11 2002-02-25 The Brigham And Women's Hospital, Inc. (hydroxyethyl)ureas as inhibitors of alzheimer's beta-amyloid production
US7858331B2 (en) * 2000-11-03 2010-12-28 Dana Farber Cancer Institute, Inc. Compositions and methods for the treatment of cancer
CA2430060C (en) 2000-11-27 2015-11-24 Minerva Biotechnologies Corporation Identification and use of cell surface receptor-binding ligands for the diagnosis and treatment of cancer
EP1350262B8 (en) 2000-12-08 2008-08-13 Coley Pharmaceuticals GmbH Cpg-like nucleic acids and methods of use thereof
IL156394A0 (en) 2000-12-18 2004-01-04 Cubist Pharm Inc Methods for preparing purified lipopeptides
US7077859B2 (en) 2000-12-22 2006-07-18 Avantec Vascular Corporation Apparatus and methods for variably controlled substance delivery from implanted prostheses
US20030050268A1 (en) * 2001-03-29 2003-03-13 Krieg Arthur M. Immunostimulatory nucleic acid for treatment of non-allergic inflammatory diseases
US7923055B2 (en) 2001-05-11 2011-04-12 Exogenesis Corporation Method of manufacturing a drug delivery system
DE60234183D1 (de) 2001-06-05 2009-12-10 Univ Chicago Verwendung von methylnaltrexon zur behandlung von immunsuppression
EP1932853A1 (en) 2001-08-06 2008-06-18 Cubist Pharmaceutical Inc. Novel depsipeptides and process for preparing same
WO2003015711A2 (en) 2001-08-17 2003-02-27 Coley Pharmaceutical Group, Inc. Combination motif immune stimulatory oligonucleotides with improved activity
AU2002346960A1 (en) 2001-10-06 2003-04-22 Merial Limited Methods and compositions for promoting growth and innate immunity in young animals
JP2005516897A (ja) * 2001-11-07 2005-06-09 イネックス ファーマシューティカルズ コーポレイション 改善された粘膜のワクチン及びその使用方法
US8685427B2 (en) 2002-07-31 2014-04-01 Boston Scientific Scimed, Inc. Controlled drug delivery
CA2478700C (en) 2002-03-11 2012-10-16 Momenta Pharmaceuticals, Inc. Analysis of sulfated polysaccharides
CA2477604A1 (en) 2002-03-13 2003-09-25 Signum Biosciences, Inc. Modulation of protein methylation and phosphoprotein phosphate
ES2734652T3 (es) 2002-04-04 2019-12-11 Zoetis Belgium S A Oligorribonucleótidos inmunoestimulantes que contienen G y U
US8871241B2 (en) 2002-05-07 2014-10-28 Psivida Us, Inc. Injectable sustained release delivery devices
PT3072978T (pt) 2002-05-09 2018-10-15 Brigham & Womens Hospital Inc 1l1rl-1 como um marcador de doença cardiovascular
US20040009943A1 (en) * 2002-05-10 2004-01-15 Inex Pharmaceuticals Corporation Pathogen vaccines and methods for using the same
US20040009944A1 (en) * 2002-05-10 2004-01-15 Inex Pharmaceuticals Corporation Methylated immunostimulatory oligonucleotides and methods of using the same
US20040013649A1 (en) * 2002-05-10 2004-01-22 Inex Pharmaceuticals Corporation Cancer vaccines and methods of using the same
US8920826B2 (en) 2002-07-31 2014-12-30 Boston Scientific Scimed, Inc. Medical imaging reference devices
GB0222522D0 (en) 2002-09-27 2002-11-06 Controlled Therapeutics Sct Water-swellable polymers
US20030049698A1 (en) * 2002-10-08 2003-03-13 Wang Timothy C. Diagnosis and treatment of gastrointestinal disease
BR0315810A (pt) 2002-10-29 2005-09-13 Coley Pharmaceutical Group Ltd Uso de oligonucleotìdeos cpg no tratamento de infecção por vìrus da hepatite c
EP1660535A2 (en) 2002-11-27 2006-05-31 Minerva Biotechnologies Corporation Techniques and compositions for the diagnosis and treatment of cancer (muc1)
CA2453080C (en) * 2003-01-21 2006-02-21 Ecopia Biosciences Inc. Polyene polyketides, processes for their production and their use as a pharmaceutical
US7655646B2 (en) * 2003-01-21 2010-02-02 Thallion Pharmaceuticals, Inc. Dibenzodiazepinone analogues, processes for their production and their use as pharmaceuticals
NZ561169A (en) * 2003-01-21 2008-06-30 Thallion Pharmaceuticals Inc Farnesyl dibenzodiazepinones, processes for their production and their use as pharmaceuticals
US7358241B2 (en) * 2003-01-21 2008-04-15 Thallion Pharmaceuticals, Inc. Compositions and methods comprising farnesyl dibenzodiazepinones for treating neoplastic cells and conditions
DE102004002243A1 (de) * 2003-02-07 2004-09-16 Trikon Technologies Limited, Newport Elektrostatische Klemmhalterung für dünne Wafer in einer Vakuumkammer zur Plasmabearbeitung
EP2325302B1 (en) 2003-02-11 2016-01-06 Shire Human Genetic Therapies, Inc. Cells that coexpress a sulfatase and a C-formylglycine generating enzyme and methods and uses thereof
EP2659893A3 (en) 2003-02-28 2014-02-12 The Johns Hopkins University T cell regulation
EP1599474B1 (en) * 2003-03-04 2013-04-24 California Institute Of Technology Heterocyclic oligomeric compounds for DNA recognition
HRP20150037T4 (hr) 2003-04-08 2022-09-02 Progenics Pharmaceuticals, Inc. Farmaceutske formulacije koje sadrže metilnaltrekson
WO2005019819A1 (en) 2003-08-20 2005-03-03 Biosite, Inc. Methods and compositions for measuring biologically active natriuretic peptides and for improving their therapeutic potential
WO2004101502A1 (en) * 2003-05-13 2004-11-25 Ecopia Biosciences Inc. Polyene polyketides, processes for their production and their use as pharmaceuticals
TWI336627B (en) 2003-05-23 2011-02-01 Organon Nv Drug delivery system,and use and manufacturing method thereof
WO2004111199A2 (en) 2003-06-12 2004-12-23 University Of Colorado System Technology Systems and methods for treating human inflammatory and proliferative diseases and wounds, with fatty acid metabolism inhibitors and/or glycolytic inhibitors
CA2470935A1 (en) * 2003-06-13 2004-12-13 Ecopia Biosciences Inc. Polyene oxazoles and processes for their preparation
WO2004112724A2 (en) * 2003-06-20 2004-12-29 Viral Genomix, Inc. Compositions for and methods for treating hiv
CA2529528A1 (en) 2003-06-20 2004-12-29 Ronald Aung-Din Topical therapy for the treatment of migraines, muscle sprains, muscle spasm, spasticity and related conditions
US20120077206A1 (en) 2003-07-12 2012-03-29 Accelr8 Technology Corporation Rapid Microbial Detection and Antimicrobial Susceptibility Testing
US7687239B2 (en) 2003-07-12 2010-03-30 Accelrs Technology Corporation Sensitive and rapid determination of antimicrobial susceptibility
US7663017B2 (en) 2003-07-30 2010-02-16 Institut Pasteur Transgenic mice having a human major histocompatability complex (MHC) phenotype, experimental uses and applications
US20060173171A1 (en) * 2003-08-26 2006-08-03 Bamdad Cynthia C Techniques and compositions for diagnosis and treatment of cancer (muci)
WO2005024025A1 (en) * 2003-09-11 2005-03-17 Ecopia Biosciences Inc. Polyene polyketides and methods of production
EP1675614A2 (en) * 2003-10-11 2006-07-05 Inex Pharmaceuticals Corp. Methods and compositions for enhancing innate immunity and antibody dependent cellular cytotoxicity
EP2248895B8 (en) 2003-12-19 2016-09-21 Autotelic LLC Combination therapy associating a TGF-beta antagonist with a chemotherapeutic agent
US7452730B2 (en) * 2004-01-16 2008-11-18 California Institute Of Technology DNA-binding polymers
CA2552351A1 (en) 2004-01-30 2005-09-09 Dana-Farber Cancer Institute, Inc. Method for determination and quantification of radiation or genotoxin exposure
CA2558667A1 (en) * 2004-02-27 2005-09-15 Antisense Pharma Gmbh Antisense oligonucleotides for inhibiting the formation of metastases in cancer
EP1568383A3 (en) 2004-02-27 2005-11-16 Antisense Pharma GmbH Use of an oligonucleotide or its active derivative for the preparation of a pharmaceutical composition for inhibiting the formation of metastases in cancer treatment
US7504086B2 (en) * 2004-03-31 2009-03-17 Canon Kabushiki Kaisha Structure and method for releasing substance therefrom
EP1745075B1 (en) 2004-04-21 2013-04-03 The Brigham And Women's Hospital, Inc. Poly-n-acetyl glucosamine (pnag/dpnag)-binding peptides and methods of use thereof
US20060004185A1 (en) 2004-07-01 2006-01-05 Leese Richard A Peptide antibiotics and peptide intermediates for their prepartion
ES2293193T5 (es) 2004-07-13 2012-06-13 Bayer Schering Pharma Oy Sistema de suministro retardado con descarga inicial controlada
ES2475207T3 (es) 2004-07-15 2014-07-10 Tetralogic Pharmaceuticals Corporation Compuestos de unión a IAP
GB0417401D0 (en) 2004-08-05 2004-09-08 Controlled Therapeutics Sct Stabilised prostaglandin composition
CN101106997A (zh) 2004-08-17 2008-01-16 约翰·霍普金斯大学 Pde5抑制剂组合物及治疗心脏病征候的方法
AU2005282731B2 (en) * 2004-09-02 2010-04-01 Yale University Regulation of oncogenes by microRNAs
CA2584412C (en) * 2004-09-14 2017-05-09 Minerva Biotechnologies Corporation Methods for diagnosis and treatment of cancer
US20080138847A1 (en) * 2004-09-23 2008-06-12 Yigong Shi Bcl-2 family member and BH-3 only proteins for use in development of peptidomimetics
US9164104B2 (en) 2004-10-06 2015-10-20 The Brigham And Women's Hospital, Inc. Relevance of achieved levels of markers of systemic inflammation following treatment
US20060106028A1 (en) * 2004-11-08 2006-05-18 Ecopia Biosciences, Inc. Polycyclic aromatics and derivatives thereof and processes for their preparation
AU2005304687B2 (en) 2004-11-11 2012-01-19 The General Hosptial Corporation Parathyroid hormone receptor activation and stem and progenitor cell expansion
US20080051326A1 (en) * 2004-11-12 2008-02-28 Alexander Dylan C Antiinfective Lipopeptides
TWI436991B (zh) * 2004-11-22 2014-05-11 Euro Celtique Sa 用於純化反-（-）-△９-四氫大麻酚與反-（＋）-△９-四氫大麻酚之方法
US7923041B2 (en) 2005-02-03 2011-04-12 Signum Biosciences, Inc. Compositions and methods for enhancing cognitive function
CA2601777A1 (en) 2005-02-03 2006-08-10 Signum Biosciences, Inc. Compositions and methods for enhancing cognitive function
US8841259B2 (en) * 2005-02-24 2014-09-23 Joslin Diabetes Center Compositions and methods for treating vascular permeability
DK1851200T3 (da) * 2005-02-25 2014-04-14 Tetralogic Pharm Corp Dimere iap-inhibitorer
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
ES2714198T3 (es) 2005-03-07 2019-05-27 Univ Chicago Uso de antagonistas opioideos para atenuar la proliferación y la migración de células endoteliales
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
DK1875244T3 (en) 2005-03-30 2019-04-29 Minerva Biotechnologies Corp Proliferation of MUC1-Expressing Cells
US8859495B2 (en) * 2005-03-30 2014-10-14 Minerva Biotechnologies Corporation Methods for stimulating or enhancing proliferation of non-tumorous cells expressing MUC1 receptors
CN101448517A (zh) 2005-04-19 2009-06-03 伊莱利利公司 用于疾病免疫干预的单价和多价合成多糖抗原
DE602006004578D1 (de) 2005-05-05 2009-02-12 Antisense Pharma Gmbh Verwendung von tgf-beta2 antisense oligonukleotiden
US7763604B2 (en) * 2005-05-16 2010-07-27 Thallion Pharma Ceuticals, Inc. Methods for administration of a farnesyl dibenzodiazepinone
AR057035A1 (es) 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
AR057325A1 (es) 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
AU2006254675A1 (en) * 2005-06-02 2006-12-07 Thallion Pharmaceuticals Inc. Formulation comprising farnesyl dibenzodiazepinone and a pharmaceutically acceptable surfactant
CN101198324B (zh) * 2005-06-16 2011-06-08 欧洲凯尔特公司 用于改进剂型的大麻素活性药物成分
TWI366460B (en) * 2005-06-16 2012-06-21 Euro Celtique Sa Cannabinoid active pharmaceutical ingredient for improved dosage forms
ES2335232T3 (es) 2005-06-21 2010-03-23 Xoma Technology Ltd. Anticuerpos y fragmentos de los mismos que se unen a la il-1 beta.
WO2007002528A1 (en) * 2005-06-23 2007-01-04 Yale University Anti-aging micrornas
US20070078111A1 (en) 2005-07-19 2007-04-05 Gabor Tigyi LPA2 receptor agonist inhibitors of CFTR
NZ565953A (en) 2005-07-27 2012-01-12 Univ Florida Small compounds that correct protein misfolding and uses thereof
US20100256046A1 (en) * 2009-04-03 2010-10-07 Tetralogic Pharmaceuticals Corporation Treatment of proliferative disorders
US20070042428A1 (en) * 2005-08-09 2007-02-22 Stacy Springs Treatment of proliferative disorders
EP1933810B1 (en) * 2005-08-11 2012-10-10 Massachusetts Institute of Technology Intravesical drug delivery device and method
TW201402124A (zh) 2005-08-19 2014-01-16 Array Biopharma Inc 作為類鐸受體（ｔｏｌｌ-ｌｉｋｅ ｒｅｃｅｐｔｏｒ）調節劑之８-經取代苯并氮雜呯
EP1957093B1 (en) 2005-08-29 2017-04-12 SHASHOUA, Victor E. Neuroprotective and neurorestorative methods and compositions
US20080021198A1 (en) * 2005-10-12 2008-01-24 Yigong Shi Modulators of protein phosphatase 2A and PP2A methyl esterase
US8658608B2 (en) 2005-11-23 2014-02-25 Yale University Modified triple-helix forming oligonucleotides for targeted mutagenesis
KR20080072934A (ko) 2005-11-25 2008-08-07 콜리 파마슈티칼 게엠베하 면역자극성 올리고리보뉴클레오티드
US20080280834A1 (en) * 2005-12-01 2008-11-13 University Of Pittsburgh Of The Commonwealth System Of Higher Education Compounds and methods for inhibiting apoptosis
WO2007120638A2 (en) * 2006-04-12 2007-10-25 President And Fellows Of Harvard College Methods and compositions for modulating glycosylation
AU2007263281B2 (en) 2006-06-20 2012-12-06 Transgene S.A. Recombinant viral vaccine
GB0613333D0 (en) 2006-07-05 2006-08-16 Controlled Therapeutics Sct Hydrophilic polyurethane compositions
GB0613638D0 (en) 2006-07-08 2006-08-16 Controlled Therapeutics Sct Polyurethane elastomers
US20100056495A1 (en) * 2006-07-24 2010-03-04 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
AR064235A1 (es) * 2006-07-24 2009-03-25 Tetralogic Pharmaceuticals Cor Dipeptidos antagonistas de iap, una composicion farmaceutica que los comprende y el uso de los mismos para el tratamiento del cancer
JP5228202B2 (ja) * 2006-07-24 2013-07-03 テトラロジック ファーマシューティカルズ コーポレーション 二量体ｉａｐアンタゴニスト
US20100143499A1 (en) * 2006-07-24 2010-06-10 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
WO2008014240A2 (en) 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
TWI489984B (zh) 2006-08-04 2015-07-01 Wyeth Corp 用於非經腸道傳輸化合物之配方及其用途
US20080153773A1 (en) * 2006-08-08 2008-06-26 Yigong Shi Modulators of phosphotyrosyl phosphatase activator
WO2008147426A2 (en) * 2006-10-04 2008-12-04 The Brigham And Women's Hospital, Inc. Methods and compositions for immunomodulation
US20100092480A1 (en) * 2006-10-13 2010-04-15 The Trustees Of The University Of Princeton Modulators of protein phosphatase 2a
GB0620685D0 (en) 2006-10-18 2006-11-29 Controlled Therapeutics Sct Bioresorbable polymers
US7645616B2 (en) * 2006-10-20 2010-01-12 The University Of Hong Kong Use of lipocalin-2 as a diagnostic marker and therapeutic target
CA2673592C (en) 2006-12-20 2014-03-25 Xoma Technology Ltd. Methods for the treatment of il-1.beta. related diseases
WO2008085912A1 (en) 2007-01-05 2008-07-17 Massachusetts Institute Of Technology Compositions of and methods of using sulfatases from flavobacterium heparinum
JP2010515464A (ja) * 2007-01-11 2010-05-13 イエール・ユニバーシテイ Ｈｉｖ細胞表面受容体の標的化不活性化のための組成物および方法
AU2014202051C1 (en) * 2007-02-06 2021-04-22 Columbia Laboratories (Bermuda) Limited Progesterone for the treatment of preterm birth
US8828981B2 (en) * 2007-02-06 2014-09-09 George Creasy Progesterone for the treatment or prevention of spontaneous preterm birth
US20100119474A1 (en) * 2007-03-06 2010-05-13 Cornell University Chronic obstructive pulmonary disease susceptibility and related compositions and methods
JP2010521670A (ja) 2007-03-12 2010-06-24 ダナ ファーバー キャンサー インスティテュート，インコーポレイテッド Ｆａｎｃｉおよびｆａｎｃｉを調整する薬剤の予後での、診断での、および癌治療での使用
US20100111943A1 (en) * 2007-03-22 2010-05-06 Medical College Of Georgia Research Institute, Inc Compositions and methods for inhibiting cancer metastasis
CL2008000905A1 (es) 2007-03-29 2008-08-22 Progenics Pharm Inc Compuestos derivados de morfina, antagonistas del receptor opioide periferico; metodo de preparacion; composicion farmaceutica; y uso para reducir los efectos de la actividad opioide endogena.
SI2139890T1 (sl) 2007-03-29 2014-12-31 Wyeth Llc Antagonisti perifernih opioidnih receptorjev in njih uporaba
CA2865389A1 (en) 2007-03-29 2008-10-09 Progenics Pharmaceuticals, Inc. Crystal forms and uses thereof
WO2008122039A2 (en) * 2007-04-02 2008-10-09 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Selenocysteine mediated hybrid antibody molecules
ES2687270T3 (es) 2007-04-12 2018-10-24 The Brigham And Women's Hospital, Inc. Fijación como objetivo de ABCB5 para la terapia del cáncer
WO2008130619A2 (en) * 2007-04-20 2008-10-30 Trustees Of Boston College A composition comprising an inhibitor of pde4 and/or pde7
EP2152304B1 (en) 2007-05-02 2018-08-22 The Regents of the University of Michigan Nanoemulsion therapeutic compositions and methods of using the same
US9139876B1 (en) 2007-05-03 2015-09-22 Momenta Pharmacueticals, Inc. Method of analyzing a preparation of a low molecular weight heparin
CN101678098A (zh) * 2007-05-17 2010-03-24 科勒制药集团公司 具有免疫刺激效力的a类寡核苷酸
EP2559773B1 (en) 2007-06-08 2015-04-22 The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services Methods for determining a hepatocellular carcinoma subtype
US8524444B2 (en) * 2007-06-15 2013-09-03 President And Fellows Of Harvard College Methods and compositions for detections and modulating O-glycosylation
US20100291219A1 (en) * 2007-06-21 2010-11-18 Massachusetts Institute Of Technology Methods and compositions relating to progenitor cells
CA2696460A1 (en) 2007-08-13 2009-02-19 Pfizer Inc. Combination motif immune stimulatory oligonucleotides with improved activity
AR066166A1 (es) * 2007-09-21 2009-07-29 Organon Nv Sistema de suministro de droga
ES2481454T3 (es) 2007-12-11 2014-07-30 Massachusetts Institute Of Technology Dispositivo implantable de administración de fármacos
EP2391650B1 (en) 2007-12-20 2014-10-15 Xoma (Us) Llc Methods for the treatment of gout
ES2648640T3 (es) 2008-02-04 2018-01-04 Ferring B.V. Anillos intravaginales monolíticos que comprenden progesterona y métodos de fabricación y usos de los mismos
US20090274682A1 (en) * 2008-02-05 2009-11-05 The Trustees Of Princeton University Demethylation and inactivation of protein phosphatase 2a
WO2009099411A1 (en) 2008-02-06 2009-08-13 Progenics Pharmaceuticals, Inc. Preparation and use of (r),(r)-2,2'-bis-methylnaltrexone
WO2009108745A1 (en) * 2008-02-26 2009-09-03 The Trustees Of Princeton University Structure of a protein phosphatase 2a holoenzyme: insights into tau dephosphorylation
EP2257626A2 (en) * 2008-03-01 2010-12-08 Abraxis BioScience, LLC Treatment, diagnostic, and method for discovering antagonist using sparc specific mirnas
AU2009225434B2 (en) 2008-03-21 2014-05-22 The University Of Chicago Treatment with opioid antagonists and mTOR inhibitors
EP2385370A1 (en) 2008-04-10 2011-11-09 Massachusetts Institute of Technology (MIT) Methods for identification and use of agents targeting cancer stem cells
US20100227853A1 (en) * 2008-04-18 2010-09-09 Trustees Of Boston College Inhibitors of cyclic amp phosphodiesterases
WO2009130616A2 (en) 2008-04-25 2009-10-29 Innate Pharma Improved tlr3 agonist compositions
WO2009137660A2 (en) * 2008-05-07 2009-11-12 Abraxis Bioscience, Llc Enhancement of drug therapy by mirna
US8598342B2 (en) 2008-06-12 2013-12-03 President And Fellows Of Harvard College Methods and compounds for antimicrobial intervention
CA2729346A1 (en) 2008-06-30 2010-01-14 Afgin Pharma, Llc Topical regional neuro-affective therapy
EP2323679A4 (en) 2008-07-25 2012-08-22 Univ Colorado CLIP INHIBITORS AND METHODS FOR MODULATING IMMUNE FUNCTION
WO2010017103A2 (en) * 2008-08-04 2010-02-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic Fully human anti-human nkg2d monoclonal antibodies
JP5908279B2 (ja) 2008-08-09 2016-04-26 マサチューセッツ インスチテュート オブ テクノロジーＭａｓｓａｃｈｕｓｅｔｔｓ Ｉｎｓｔｉｔｕｔｅ Ｏｆ Ｔｅｃｈｎｏｌｏｇｙ 移植可能な薬物送達デバイス並びに男性の尿生殖器及び周囲組織を治療する方法
CA2736505A1 (en) 2008-09-17 2010-03-25 Tetralogic Pharmaceuticals Corp. Iap inhibitors
WO2010033958A1 (en) * 2008-09-22 2010-03-25 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Nuclear factor kappa b pathway inhibitor composition and use of same
WO2010036945A2 (en) * 2008-09-26 2010-04-01 The Regents Of The University Of Michigan Nanoemulsion therapeutic compositions and methods of using the same
CA2676881C (en) 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
KR20110069144A (ko) 2008-10-09 2011-06-22 미네르바 바이오테크놀로지 코포레이션 세포내에서 다능성을 유도하기 위한 방법
EP3130923B1 (en) 2008-11-14 2020-02-12 The Brigham and Women's Hospital, Inc. Therapeutic methods relating to cancer stem cells
US9974844B2 (en) 2008-11-17 2018-05-22 The Regents Of The University Of Michigan Cancer vaccine compositions and methods of using the same
CA2746491C (en) * 2008-12-11 2018-01-16 Massachusetts Institute Of Technology Contact lens drug delivery device
US20100158980A1 (en) 2008-12-18 2010-06-24 Casey Kopczynski Drug delivery devices for delivery of therapeutic agents
JP5670914B2 (ja) 2008-12-22 2015-02-18 キュービスト ファーマシューティカルズ， インコーポレイテッド グラム陽性菌感染症を処置するための新規抗菌剤
WO2010075303A1 (en) 2008-12-23 2010-07-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Splicing factors with a puf protein rna-binding domain and a splicing effector domain and uses of same
TW201035111A (en) * 2008-12-23 2010-10-01 Biosource Pharm Inc Antibiotic compositions for the treatment of gram negative infections
WO2010075417A1 (en) 2008-12-23 2010-07-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Survivin specific t cell receptor for treating cancer
US20100260677A1 (en) 2009-03-02 2010-10-14 Massachusetts Institute Of Technology Methods and systems for treatment and/or diagnosis
US8309356B2 (en) * 2009-04-01 2012-11-13 Yale University Pseudocomplementary oligonucleotides for targeted gene therapy
AU2010238723A1 (en) 2009-04-23 2011-11-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-human ROR1 antibodies
US8686016B2 (en) 2009-04-30 2014-04-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Schweinfurthins and uses thereof
ES2808827T3 (es) 2009-05-14 2021-03-02 Bayer Ip Gmbh Respuesta inmune mejorada en especies aviares
WO2010132532A1 (en) 2009-05-15 2010-11-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services B cell surface reactive antibodies
US8957075B2 (en) 2009-06-01 2015-02-17 President And Fellows Of Harvard College O-GlcNAc transferase inhibitors and uses thereof
ES2566646T3 (es) 2009-06-16 2016-04-14 The Regents Of The University Of Michigan Vacunas en nanoemulsión
IN2012DN00352A (enExample) 2009-06-16 2015-08-21 Bikam Pharmaceuticals Inc
AU2010265866B2 (en) 2009-06-26 2012-07-12 Taris Biomedical Llc Solid drug tablets for implantable drug delivery devices
US8283372B2 (en) 2009-07-02 2012-10-09 Tetralogic Pharmaceuticals Corp. 2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic
US9089573B2 (en) 2009-07-22 2015-07-28 University Of Massachusetts Methods and compositions to reduce oxidative stress
EP2456787A4 (en) 2009-07-24 2013-01-30 Univ Leland Stanford Junior CYTOKIN COMPOSITIONS AND METHOD FOR THEIR USE
RU2012107535A (ru) 2009-07-30 2013-09-10 Антисенс Фарма Гмбх КОМБИНАЦИЯ ХИМИОТЕРАПЕВТИЧЕСКОГО СРЕДСТВА И ИНГИБИТОРА СИСТЕМЫ TGF-β
EP2287304A1 (en) 2009-08-17 2011-02-23 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Novel treatment of patients after stent implantation or balloon dilatation and novel drug eluting stents
CN102781933B (zh) 2009-08-18 2016-01-20 文蒂雷克斯药品公司 作为toll样受体调节剂的取代的苯并氮杂*
US8691809B2 (en) 2009-08-18 2014-04-08 Ventirx Pharmaceuticals, Inc. Substituted benzoazepines as toll-like receptor modulators
US9017312B2 (en) * 2009-09-10 2015-04-28 Taris Biomedical Llc Implantable device for controlled drug delivery
CA2776143A1 (en) 2009-10-01 2011-04-07 The United States Of America, As Represented By The Secretary, Departmen T Of Health And Human Services Anti-vascular endothelial growth factor receptor-2 chimeric antigen receptors and use of same for the treatment of cancer
EP2526122B1 (en) * 2010-01-19 2020-06-10 Momenta Pharmaceuticals, Inc. Evaluating heparin preparations
US20110293585A1 (en) 2010-04-21 2011-12-01 Helix Therapeutics, Inc. Compositions and methods for treatment of lysosomal storage disorders
WO2011133803A1 (en) 2010-04-21 2011-10-27 Helix Therapeutics, Inc. Compositions and methods for targeted inactivation of hiv cell surface receptors
EP3138915A1 (en) 2010-05-04 2017-03-08 The Brigham and Women's Hospital, Inc. Detection and treatment of fibrosis
WO2011146483A1 (en) * 2010-05-17 2011-11-24 Aerie Pharmaceuticals, Inc. Drug delivery devices for delivery of ocular therapeutic agents
US8658603B2 (en) 2010-06-16 2014-02-25 The Regents Of The University Of Michigan Compositions and methods for inducing an immune response
US8415307B1 (en) 2010-06-23 2013-04-09 Biosource Pharm, Inc. Antibiotic compositions for the treatment of gram negative infections
EP2595613B1 (en) 2010-07-22 2019-01-09 The U.S.A. as represented by the Secretary, Department of Health and Human Services Compounds for use in a method of preventing or treating viral infection
US8580294B2 (en) 2010-10-19 2013-11-12 International Partnership For Microbicides Platinum-catalyzed intravaginal rings
DE102010050242A1 (de) 2010-10-30 2012-05-03 Schott Ag Wirkstoffverpackung
WO2012067947A1 (en) 2010-11-18 2012-05-24 Ischemix Llc Lipoyl compounds and their use for treating ischemic injury
EP2646469B1 (en) 2010-12-01 2017-11-01 The United States of America, as represented by The Secretary, Department of Health and Human Services Chimeric rabbit/human ror1 antibodies
MX345854B (es) 2010-12-22 2017-02-17 Bayer Ip Gmbh Respuesta inmune potenciada en la especie bovina.
WO2012092539A2 (en) 2010-12-31 2012-07-05 Takeda Pharmaceutical Company Limited Antibodies to dll4 and uses thereof
EP2663300B1 (en) 2011-01-10 2023-03-08 TARIS Biomedical LLC Lidocaine regimen for the use of sustained treatment of bladder pain and irritative voiding
MX346387B (es) 2011-01-12 2017-03-02 Ventirx Pharmaceuticals Inc Benzoazepinas sustituidas como moduladores de receptores tipo toll.
BR112013017947A2 (pt) 2011-01-12 2018-12-18 Array Biopharma Inc benzoazepinas substituídas como moduladores de receptor toll-like
EP2476409A1 (en) * 2011-01-14 2012-07-18 Université Catholique De Louvain Implant comprising a core and a tube encasing the core
WO2012106591A1 (en) 2011-02-03 2012-08-09 Mirna Therapeutics, Inc. Synthetic mimics of mir-34
JP2014506789A (ja) 2011-02-03 2014-03-20 マーナ セラピューティクス インコーポレイテッド ｍｉＲ−１２４の合成模倣体
EP2670398B1 (en) 2011-02-04 2017-06-07 TARIS Biomedical LLC Implantable device for controlled release of low solubility drug
WO2012115952A1 (en) 2011-02-21 2012-08-30 Momenta Pharmaceuticals, Inc. Evaluating heparin preparations
US10254204B2 (en) 2011-03-07 2019-04-09 Accelerate Diagnostics, Inc. Membrane-assisted purification
WO2012122314A2 (en) 2011-03-07 2012-09-13 Accelr8 Technology Corporation Rapid cell purification systems
WO2012125623A2 (en) 2011-03-14 2012-09-20 Ludwig Institute For Cancer Research Ltd. Cleavage inhibitors of transforming growth factor beta type i receptor and uses thereof in cancer therapy
EP2686418A4 (en) 2011-03-17 2015-04-22 Minerva Biotechnologies Corp METHOD FOR THE PRODUCTION OF PLURIPOTENTAL STEM CELLS
ES2872077T3 (es) 2011-04-08 2021-11-02 Us Health Receptor de antígenos quiméricos anti-variante III del receptor de factor de crecimiento epidérmico y uso de los mismos para el tratamiento de cáncer
WO2012145739A1 (en) 2011-04-21 2012-10-26 Trustees Of Tufts College Compositions and methods for stabilization of active agents
ES2583877T3 (es) 2011-06-01 2016-09-22 Janus Biotherapeutics, Inc. Moduladores novedosos del sistema inmunitario
CA2837227C (en) 2011-06-01 2022-05-10 Janus Biotherapeutics, Inc. Novel immune system modulators
US9937335B2 (en) * 2011-06-06 2018-04-10 Oak Crest Institute Of Science Drug delivery device employing wicking release window
WO2012174064A1 (en) 2011-06-14 2012-12-20 Bikam Pharmaceuticals, Inc. Opsin-binding ligands, compositions and methods of use
US9593160B2 (en) 2011-07-18 2017-03-14 President And Fellows Of Harvard College Engineered microbe-targeting molecules and uses thereof
US10765654B2 (en) 2011-07-19 2020-09-08 University Of Vermont And State Agricultural College Methods and compounds for treating cancer
WO2013020044A1 (en) 2011-08-03 2013-02-07 The Charlotte-Mecklenburg Hospital Authority D/B/A Carolinas Medical Center Treatment of fibrosis using microrna-19b
US9873694B2 (en) 2011-10-04 2018-01-23 Janus Biotherapeutics, Inc. Imidazole quinoline-based immune system modulators
JP6466170B2 (ja) 2011-10-17 2019-02-06 ミネルバ バイオテクノロジーズ コーポレーション 幹細胞の増殖及び誘導用の培地
EP2768307B1 (en) 2011-10-19 2020-03-18 Bikam Pharmaceuticals, Inc. Opsin-binding ligands, compositions and methods of use
IN2014CN02906A (enExample) 2011-10-20 2015-07-03 Us Health
WO2013082000A1 (en) 2011-11-30 2013-06-06 Bikam Pharmaceuticals, Inc. Opsin-binding ligands, compositions and methods of use
WO2013082275A1 (en) 2011-11-30 2013-06-06 Trustees Of Boston College Inhibitors of phosphodiesterases 11 (pde11) and methods of use to elevate cortisol production
US10040749B2 (en) 2011-12-01 2018-08-07 Bikam Pharmaceuticals Inc. Opsin-binding ligands, compositions and methods of use
EP3050900A1 (en) 2011-12-19 2016-08-03 Xoma (Us) Llc Methods for treating acne
CA2862979A1 (en) 2012-01-09 2013-07-18 The Scripps Research Institute Humanized antibodies with ultralong cdr3s
US20140050720A1 (en) 2012-01-09 2014-02-20 The Scripps Research Institute Ultralong complementarity determining regions and uses thereof
EP3421489B1 (en) 2012-03-23 2021-05-05 The United States of America, as represented by The Secretary, Department of Health and Human Services Anti-mesothelin chimeric antigen receptors
SG11201406123TA (en) 2012-03-30 2014-10-30 Cubist Pharm Inc 1,3,4-OXADIAZOLE AND 1,3,4-THIADIAZOLE β-LACTAMASE INHIBITORS
WO2013149136A1 (en) 2012-03-30 2013-10-03 Cubist Pharmaceuticals, Inc. ISOXAZOLE β-LACTAMASE INHIBITORS
CA2871490C (en) 2012-04-27 2022-10-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of cpg oligonucleotides co-formulated with an antibiotic to accelerate wound healing
WO2013169691A1 (en) 2012-05-07 2013-11-14 Trustees Of Dartmouth College Anti-b7-h6 antibody, fusion proteins, and methods of using the same
AU2013290266B2 (en) 2012-07-11 2018-05-10 University Of Vermont And State Agricultural College Method and composition for metabolic regulation
CA2879066C (en) 2012-07-13 2019-08-13 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant
AU2013305888A1 (en) 2012-08-21 2015-02-26 Genesys Research Institute Compositions and methods for treating or preventing anthracycline induced cardiotoxicity
EP2904119B1 (en) 2012-10-02 2020-06-17 The General Hospital Corporation d/b/a Massachusetts General Hospital Methods relating to dna-sensing pathway related conditions
US9962448B2 (en) 2012-10-04 2018-05-08 Northeastern University Compounds and methods for targeted immune system delivery
US10072078B2 (en) 2012-10-24 2018-09-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services M971 chimeric antigen receptors
US10106778B2 (en) 2012-11-08 2018-10-23 Whitehead Institute For Biomedical Research Selective targeting of cancer stem cells
US9750718B2 (en) 2012-12-12 2017-09-05 The Charlotte-Mecklenburg Hospital Authority Methods of treating hepatic fibrosis and associated diseases by regulating Rev-ERB activity
US9872851B2 (en) 2012-12-12 2018-01-23 The Charlotte-Mecklenburg Hospital Authority Methods of treating portal hypertension
CN118028464A (zh) 2013-03-14 2024-05-14 儿童医学中心公司 Cd36鉴定癌症对象以用于治疗的用途
US11376329B2 (en) 2013-03-15 2022-07-05 Trustees Of Tufts College Low molecular weight silk compositions and stabilizing silk compositions
ES2935659T3 (es) 2013-03-15 2023-03-09 Tufts College Composiciones de seda de bajo peso molecular y composiciones de seda estabilizadoras
US9677109B2 (en) 2013-03-15 2017-06-13 Accelerate Diagnostics, Inc. Rapid determination of microbial growth and antimicrobial susceptibility
EP2968880B1 (en) 2013-03-15 2025-04-30 TARIS Biomedical LLC Drug delivery devices with drug-permeable component
US9790282B2 (en) 2013-03-25 2017-10-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-CD276 polypeptides, proteins, and chimeric antigen receptors
JP2016522165A (ja) 2013-04-04 2016-07-28 イエオ−イスティトゥート・エウロペオ・ディ・オンコロジア・エッセ・エッレ・エッレ 胸腺間質性リンパ球新生因子フラグメント及びその使用
US10274503B2 (en) 2013-05-08 2019-04-30 Vegenics Pty Limited Methods of using VEGF-C biomarkers for age-related macular degeneration (AMD) diagnosis
CN105451726B (zh) 2013-06-25 2021-03-16 沃尔特和伊利莎豪医学研究所 治疗细胞内感染的方法
WO2015006543A1 (en) 2013-07-10 2015-01-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method for predicting and detecting tumor metastasis in kidney cancer
CN111518199A (zh) 2013-07-18 2020-08-11 图鲁斯生物科学有限责任公司 具有超长互补决定区的人源化抗体
WO2015017146A2 (en) 2013-07-18 2015-02-05 Fabrus, Inc. Antibodies with ultralong complementarity determining regions
HRP20201421T1 (hr) 2013-08-19 2020-12-11 Taris Biomedical Llc Uređaji za davanje više jedinica lijeka
EP3035849B1 (en) 2013-08-21 2019-07-31 Senseonics, Incorporated Drug elution for in vivo protection of bio-sensing analytes
KR102302634B1 (ko) 2013-09-13 2021-09-14 더 스크립스 리서치 인스티튜트 변형된 치료제 및 이의 조성물
KR102357968B1 (ko) 2013-10-15 2022-02-03 더 스크립스 리서치 인스티튜트 키메라 항원 수용체 t 세포 스위치 및 이의 용도
CN105829349B (zh) 2013-10-15 2023-02-03 斯克利普斯研究所 肽嵌合抗原受体t细胞开关和其用途
JP6621752B2 (ja) 2013-10-21 2019-12-18 ソーク インスティテュート フォー バイオロジカル スタディーズ 変異した線維芽細胞増殖因子（ｆｇｆ）１および使用方法
JP6306700B2 (ja) 2013-11-01 2018-04-04 ユニバーシティ オブ オスロＵｎｉｖｅｒｓｉｔｙ ｏｆ Ｏｓｌｏ アルブミン改変体及びその使用
US10137031B2 (en) 2013-11-14 2018-11-27 International Partnership For Microbicides, Inc. Combination therapy intravaginal rings
WO2015071763A2 (en) 2013-11-15 2015-05-21 Oslo Universitetssykehus Hf Ctl peptide epitopes and antigen-specific t cells, methods for their discovery, and uses thereof
US10801070B2 (en) 2013-11-25 2020-10-13 The Broad Institute, Inc. Compositions and methods for diagnosing, evaluating and treating cancer
US11725237B2 (en) 2013-12-05 2023-08-15 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
EP3077416B1 (en) 2013-12-06 2019-06-19 The United States of America, as represented by The Secretary, Department of Health and Human Services Thymic stromal lymphopoietin receptor-specific chimeric antigen receptors and methods using same
EP3079659B1 (en) 2013-12-11 2020-10-28 Merck Sharp & Dohme B.V. Drug delivery system for delivery of anti-virals
US10413504B2 (en) 2013-12-11 2019-09-17 Merck Sharp & Dohme Corp. Intravaginal ring drug delivery system
WO2015095604A2 (en) 2013-12-18 2015-06-25 President And Fellows Of Harvard College Methods and assays relating to circulating tumor cells
EP3082797A4 (en) 2013-12-18 2017-12-13 The California Institute for Biomedical Research Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof
AU2014368898B2 (en) 2013-12-20 2020-06-11 Dana-Farber Cancer Institute, Inc. Combination therapy with neoantigen vaccine
SI3712174T1 (sl) 2013-12-24 2022-06-30 Janssen Pharmaceutica Nv Protitelesa in delci proti VISTA
JPWO2015108048A1 (ja) 2014-01-15 2017-03-23 株式会社新日本科学 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
JPWO2015108046A1 (ja) 2014-01-15 2017-03-23 株式会社新日本科学 抗アレルギー作用を有するキラル核酸アジュバンド及び抗アレルギー剤
WO2015108047A1 (ja) 2014-01-15 2015-07-23 株式会社新日本科学 免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤
MX2016010993A (es) 2014-02-28 2017-05-01 Bayer Animal Health Gmbh Plasmidos inmunoestimuladores.
US10314851B2 (en) 2014-03-17 2019-06-11 Massachusetts Institute Of Technology Metakaryocidal treatments
EP4154901A1 (en) 2014-03-26 2023-03-29 The Children's Medical Center Corporation Cyclic prosaposin peptides and uses thereof
US10028958B2 (en) 2014-04-19 2018-07-24 Massachusetts Institute Of Technology Methods of treating cancer with a combination of selected MEK1/2 and AXL inhibitors
US10398672B2 (en) 2014-04-29 2019-09-03 Whitehead Institute For Biomedical Research Methods and compositions for targeting cancer stem cells
US11918695B2 (en) 2014-05-09 2024-03-05 Yale University Topical formulation of hyperbranched polymer-coated particles
WO2015172153A1 (en) 2014-05-09 2015-11-12 Yale University Topical formulation of hyperbranched polyglycerol-coated particles thereof
KR20170016884A (ko) * 2014-05-30 2017-02-14 텍스타일-베이스드 딜리버리, 인코포레이티드 약물 전달 시스템 및 관련 사용 방법
WO2015200752A1 (en) * 2014-06-26 2015-12-30 Taris Biomedical Llc Intravesical drug delivery devices and methods including elastic polymer-drug matrix systems
CN107108629A (zh) 2014-08-22 2017-08-29 贾纳斯生物治疗有限公司 新颖的n2, n4, n7, 6‑四取代的蝶啶‑2,4,7‑三胺和2, 4, 6, 7‑四取代的蝶啶化合物及其合成和使用方法
EP3193933B1 (en) 2014-09-17 2021-04-28 The U.S.A. as represented by the Secretary, Department of Health and Human Services Anti-cd276 antibodies (b7h3)
WO2016046847A1 (en) 2014-09-23 2016-03-31 Council Of Scientific & Industrial Research Metal embedded hydrophilic polymer for drug delivery applications
EP3204039B1 (en) 2014-10-10 2022-06-08 The Regents Of The University Of Michigan Nanoemulsion compositions for preventing, suppressing or eliminating allergic and inflammatory disease
CA3002137A1 (en) 2014-10-17 2016-04-21 Salix Pharmaceuticals, Inc. Use of methylnaltrexone to attenuate tumor progression
BR112017007942A2 (pt) 2014-10-30 2017-12-19 Textile Based Delivery Inc sistemas de liberação
WO2016079527A1 (en) 2014-11-19 2016-05-26 Tetralogic Birinapant Uk Ltd Combination therapy
WO2016097773A1 (en) 2014-12-19 2016-06-23 Children's Cancer Institute Therapeutic iap antagonists for treating proliferative disorders
US10975442B2 (en) 2014-12-19 2021-04-13 Massachusetts Institute Of Technology Molecular biomarkers for cancer immunotherapy
US10993997B2 (en) 2014-12-19 2021-05-04 The Broad Institute, Inc. Methods for profiling the t cell repertoire
AU2016219350A1 (en) 2015-02-10 2017-08-24 Minerva Biotechnologies Corporation Humanized anti-MUC1* antibodies
US10350262B2 (en) 2015-02-18 2019-07-16 University Of Vermont And State Agricultural College MCJ agonists and uses therefor
EP3268034A4 (en) 2015-03-05 2018-11-14 Northwestern University Non-neuroinvasive viruses and uses thereof
EP3270937A4 (en) 2015-03-26 2018-09-12 The Trustees Of Dartmouth College Anti-mica antigen binding fragments, fusion molecules, cells which express and methods of using
WO2016154621A1 (en) 2015-03-26 2016-09-29 The California Institute For Biomedical Research SWITCHABLE NON-scFv CHIMERIC RECEPTORS, SWITCHES, AND USES THEREOF
AU2016243656A1 (en) 2015-03-30 2017-11-09 Accelerate Diagnostics, Inc. Instrument and system for rapid microorganism identification and antimicrobial agent susceptibility testing
US10253355B2 (en) 2015-03-30 2019-04-09 Accelerate Diagnostics, Inc. Instrument and system for rapid microorganism identification and antimicrobial agent susceptibility testing
EP3708680B8 (en) 2015-04-15 2023-08-30 University of Massachusetts Compositions and methods for xi chromosome reactivation
EP3283113A4 (en) 2015-04-15 2018-12-05 The California Institute for Biomedical Research Optimized pne-based chimeric receptor t cell switches and uses thereof
EP3285850A1 (en) 2015-04-23 2018-02-28 TARIS Biomedical LLC Drug delivery devices with drug-permeable component and methods
PE20180670A1 (es) 2015-05-20 2018-04-19 Broad Inst Inc Neoantigenos compartidos
AU2016270428B2 (en) 2015-06-05 2020-11-26 Musc Foundation For Research Development Endostatin fragments and variants for use in treating fibrosis
US20190000928A1 (en) 2015-06-17 2019-01-03 The California Institute For Biomedical Research Modified therapeutic agents and compositions thereof
WO2016207717A1 (en) 2015-06-24 2016-12-29 Janssen Pharmaceutica Nv Anti-vista antibodies and fragments
EP3109257B1 (en) 2015-06-26 2021-01-06 Prindex S.r.l. Diagnosis and therapy of multiple sclerosis
US10973912B2 (en) 2015-06-29 2021-04-13 President And Fellows Of Harvard College Treatment for myopathy
CN108136005A (zh) 2015-07-10 2018-06-08 佛蒙特大学及州农业学院 用于治疗药物诱导的疾病和病症的mcj抑制剂
EP3763378A1 (en) 2015-08-06 2021-01-13 President and Fellows of Harvard College Improved microbe-binding molecules and uses thereof
EP3337900B1 (en) 2015-08-20 2021-04-07 Asociación Centro de Investigación Cooperativa en Biociencias - CIC bioGUNE Methods and compositions to treat liver diseases and conditions
EP3349749B1 (en) 2015-09-17 2022-12-14 University of Massachusetts Compositions and methods for modulating fmr1 expression
CN108848669B (zh) 2016-01-20 2022-06-07 斯克利普斯研究所 Ror1抗体组合物和相关方法
CA3011817A1 (en) 2016-01-20 2017-07-27 The Scripps Research Institute Ror2 antibody compositions and related methods
CN109069626A (zh) 2016-02-12 2018-12-21 詹森药业有限公司 抗-vista(b7h5)抗体
AU2017221424A1 (en) 2016-02-16 2018-09-20 Yale University Compositions and methods for treatment of cystic fibrosis
EP3416976A2 (en) 2016-02-16 2018-12-26 Yale University Compositions for enhancing targeted gene editing and methods of use thereof
EP3436066A1 (en) 2016-04-01 2019-02-06 Checkmate Pharmaceuticals, Inc. Fc receptor-mediated drug delivery
WO2017175058A1 (en) 2016-04-07 2017-10-12 Janssen Pharmaceutica Nv Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
JP7197078B2 (ja) 2016-04-08 2022-12-27 ジィールバイオ，インコーポレーテッド プレクチン１結合性抗体およびその使用
SG11201809100QA (en) 2016-04-19 2018-11-29 Us Health Use of gram negative species to treat atopic dermatitis
US10293005B2 (en) 2016-04-19 2019-05-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of gram negative species to treat atopic dermatitis
US12076397B2 (en) 2016-05-10 2024-09-03 The Regents Of The University Of Michigan Emulsion adjuvant for intramuscular, intradermal and subcutaneous administration
WO2017198631A1 (en) 2016-05-16 2017-11-23 Istituto Nazionale Di Genetica Molecolare - Ingm Markers selectively deregulated in tumor-infiltrating regulatory t cells
CA3025516A1 (en) 2016-05-27 2017-11-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Flt3-specific chimeric antigen receptors and methods using same
WO2017207623A1 (en) 2016-05-31 2017-12-07 Université de Lausanne Mirna as biomarkers and regulators of cancer stem cells
US20190322643A1 (en) 2016-06-29 2019-10-24 Georgia State University Research Foundation, Inc. Histone deacetylase and histone methyltransferase inhibitors and methods of making and use of the same
WO2018005759A1 (en) 2016-07-01 2018-01-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inhibitor of heme degradation for use to improve antibiotic treatment of mycobacterium tuberculosis infection
US10933131B2 (en) 2016-07-26 2021-03-02 Bayer Animal Health Gmbh Increased fertility in bovine species
KR102613430B1 (ko) 2016-10-19 2023-12-18 더 스크립스 리서치 인스티튜트 인간화된 표적화 모이어티 및/또는 최적화된 키메라 항원 수용체-상호작용 도메인을 갖는 키메라 항원 수용체 효과기 세포 스위치 및 이의 용도
EP3896451B1 (en) 2016-11-07 2024-06-26 University of Massachusetts Carm1 inhibitors for facioscapulohumeral muscular dystrophy
WO2018096396A1 (en) 2016-11-22 2018-05-31 University Of Oslo Albumin variants and uses thereof
US11549149B2 (en) 2017-01-24 2023-01-10 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
EP3576726A1 (en) 2017-02-06 2019-12-11 Massachusetts Institute Of Technology Methods and products related to glutaminase inhibitors
US11260132B2 (en) 2017-03-16 2022-03-01 Children's Medical Center Corporation Engineered liposomes as cancer-targeted therapeutics
US20200113821A1 (en) 2017-04-04 2020-04-16 Yale University Compositions and methods for in utero delivery
CA3061164A1 (en) 2017-04-25 2018-11-01 Prothera Biologics, Inc. Methods for quantifying inter-alpha inhibitor proteins
DK3615023T3 (da) 2017-04-25 2023-09-25 Ischemix Llc Lipoyl-glu-ala til behandlingen af neurodegenerativ skade forårsaget af traumatisk hjerneskade
US11225512B2 (en) 2017-04-27 2022-01-18 University Of New Hampshire Compositions and methods for ceramide-elevating therapeutic strategies
JP2020526537A (ja) 2017-07-14 2020-08-31 ユニバーシティ オブ マサチューセッツ 炎症を処置するための方法および組成物
EP3655437A1 (en) 2017-07-20 2020-05-27 NBE-Therapeutics AG Human antibodies binding to ror2
US11103460B2 (en) 2017-08-07 2021-08-31 Board Of Regents, The University Of Texas System Fabrication methods for nanodelivery systems for long term controlled delivery of active pharmaceutical ingredients
KR102486090B1 (ko) 2017-08-07 2023-01-10 엔비이-테라퓨틱스 아게 생체 내 내성이 높은 항체 약물 결합체
US12268736B2 (en) 2017-09-07 2025-04-08 University Of Oslo Vaccine molecules
EP3678699A1 (en) 2017-09-07 2020-07-15 University Of Oslo Vaccine molecules
KR20230079457A (ko) 2017-12-29 2023-06-07 락손 메디칼 아게 약물 전달 시스템
KR102574015B1 (ko) 2017-12-29 2023-09-04 락손 메디칼 아게 약물 전달 시스템을 제조하기 위한 방법
WO2019154884A1 (en) 2018-02-07 2019-08-15 Ecole Polytechnique Federale De Lausanne (Epfl) Method for determining cancer invasiveness and patient prognosis
WO2019160866A2 (en) 2018-02-13 2019-08-22 Checkmate Pharmaceuticals, Inc. Compositions and methods for tumor immunotherapy
EP3775218A1 (en) 2018-04-09 2021-02-17 Checkmate Pharmaceuticals Packaging oligonucleotides into virus-like particles
MX2020011065A (es) 2018-04-19 2021-01-20 Tvardi Therapeutics Inc Inhibidores stat3.
BR112020023050A2 (pt) 2018-05-11 2021-03-16 Forte Subsidiary, Inc. Composições para o tratamento de condições da pele
CA3103265A1 (en) 2018-06-12 2019-12-19 Angiex, Inc. Antibody-oligonucleotide conjugates
CN112888452B (zh) 2018-08-22 2025-11-14 贝凯恩生物医疗技术有限公司 环孢菌素组合物及使用方法
CN113164552B (zh) 2018-10-04 2025-06-06 新泽西州立罗格斯大学 使用神经介素肽减少2型细胞因子介导的炎症的方法
US11266617B2 (en) 2018-10-16 2022-03-08 Massachusetts Institute Of Technology Beta-hydroxybutyrate encapsulated PLGA nanoparticle compositions
US20210340562A1 (en) 2018-10-19 2021-11-04 Board Of Regents, The University Of Texas System Engineered long interspersed element (line) transposons and methods of use
EP3883562A4 (en) 2018-11-21 2022-08-03 Tremeau Pharmaceuticals, Inc. PURIFIED FORMS OF ROFECOXIB AND METHODS OF MAKING AND USING
EP3677693A1 (en) 2019-01-03 2020-07-08 Ecole Polytechnique Federale De Lausanne (EPFL) EPFL-TTO Transpochimeric gene trancripts (tcgts) as cancer biomarkers
JP7303314B2 (ja) 2019-01-18 2023-07-04 ヤンセン バイオテツク，インコーポレーテツド Ｇｐｒｃ５ｄキメラ抗原受容体及びそれを発現する細胞
PH12021551788A1 (en) 2019-01-30 2022-05-23 Janssen Pharmaceutica Nv Methods of treating prostate cancer based on molecular subtypes
US20220054494A1 (en) 2019-03-13 2022-02-24 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Methods for treating bladder and urethra dysfunction and disease
US20220175934A1 (en) 2019-03-21 2022-06-09 Mitotherapeutix Llc Multivalent ligand clusters for targeted delivery of therapeutic agents
CA3136618A1 (en) 2019-04-10 2020-10-15 Elevatebio Technologies, Inc. Flt3-specific chimeric antigen receptors and methods of using the same
EP3972653A1 (en) 2019-05-22 2022-03-30 Massachusetts Institute of Technology Circular rna compositions and methods
WO2020239478A1 (en) 2019-05-28 2020-12-03 Pharma Mar, S.A. Trabectedin for treating sarcomas based on genomic markers
WO2020257779A1 (en) 2019-06-21 2020-12-24 Yale University Hydroxymethyl-modified gamma-pna compositions and methods of use thereof
US20220243211A1 (en) 2019-06-21 2022-08-04 Yale University Peptide nucleic acid compositions with modified hoogsteen binding segments and methods of use thereof
JP2022541332A (ja) 2019-07-26 2022-09-22 ヤンセン バイオテツク，インコーポレーテツド カリクレイン関連ペプチダーゼ２抗原結合ドメインを含むタンパク質及びその使用
BR112022001331A2 (pt) 2019-07-26 2022-06-14 Janssen Biotech Inc Receptor quimérico de antígeno (car) anti-hk2
US12496357B2 (en) 2019-07-31 2025-12-16 Yale University Compositions and methods for treating sickle cell disease
CN112390894A (zh) 2019-08-12 2021-02-23 广东东阳光药业有限公司 嵌合抗原受体及其应用
CN119409834A (zh) 2019-08-12 2025-02-11 北京恩瑞尼生物科技股份有限公司 用于通过cd39表达细胞的adcc靶向促进和增强t细胞介导的免疫反应的方法和组合物
JP2022544592A (ja) 2019-08-16 2022-10-19 ヤンセン バイオテツク，インコーポレーテツド 改善された機能を有する治療用免疫細胞及びその作製方法
KR20220079880A (ko) 2019-10-07 2022-06-14 디.이. 쇼우 리서치, 엘엘씨 Kv1.3 칼륨 셰이커 채널 차단제로서의 아릴메틸렌 헤테로시클릭 화합물
JP2022554187A (ja) 2019-10-24 2022-12-28 ミノトール セラピューティクス インコーポレイテッド キメラサイトカイン改変抗体およびその使用方法
US10945992B1 (en) 2019-11-13 2021-03-16 Tremeau Pharmaceuticals, Inc. Dosage forms of rofecoxib and related methods
EP4061837A1 (en) 2019-11-18 2022-09-28 Janssen Biotech, Inc. Anti-cd79 chimeric antigen receptors, car-t cells, and uses thereof
IL271778A (en) 2019-12-31 2021-06-30 Ichilov Tech Ltd Methods for treating atopic dermatitis
EP3868396A1 (en) 2020-02-20 2021-08-25 Enthera S.R.L. Inhibitors and uses thereof
WO2021168373A1 (en) 2020-02-21 2021-08-26 Mitotherapeutix Llc Compositions and methods for inhibiting expression of methylation-controlled j-protein (mcj)
AU2021225926A1 (en) 2020-02-26 2022-10-20 Case Western Reserve University Compositions and methods for treating misfolded protein ocular disorders
PH12022552370A1 (en) 2020-03-13 2023-12-18 Janssen Biotech Inc Materials and methods for binding siglec-3/cd33
US20230181672A1 (en) 2020-05-07 2023-06-15 The U.S.A., As Represented By The Secretary, Department Of Health And Human Services Aberrant post-translational modifications (ptms) in methyl- and propionic acidemia and a mutant sirtuin (sirt) to metabolize ptms
PH12022553032A1 (en) 2020-05-08 2024-05-13 Georgiamune Inc Akt3 modulators
JP2023527309A (ja) 2020-05-19 2023-06-28 オルナ セラピューティクス インコーポレイテッド 環状ｒｎａ組成物及び方法
WO2021245285A1 (en) 2020-06-05 2021-12-09 Janssen Pharmaceutica Nv Methods of treating prostate cancer based on molecular subtypes
TW202212354A (zh) 2020-08-03 2022-04-01 美商健生生物科技公司 用於病毒治療劑中之多向生物運輸的材料及方法
EP4225285A4 (en) 2020-10-06 2024-11-20 D.E. Shaw Research, LLC LACTAM COMPOUNDS AS KV1.3 POTASSIUM SHAKER CHANNEL BLOCKERS
CN116615256A (zh) 2020-10-16 2023-08-18 乔治亚大学研究基金会 糖缀合物
EP4059498A1 (en) 2021-03-16 2022-09-21 Centre Hospitalier Universitaire Vaudois (CHUV) Methods and compositions for treating conditions associated with hypermineralization
JP2024512035A (ja) 2021-03-24 2024-03-18 ヤンセン バイオテツク，インコーポレーテツド Ｃｄ２２及びｃｄ７９ｂを標的とする抗体
US11161833B1 (en) 2021-04-09 2021-11-02 Tremeau Pharmaceuticals, Inc. Deuterated etoricoxib, methods of manufacture, and use thereof
CA3217865A1 (en) 2021-04-28 2022-11-03 Minotaur Therapeutics, Inc. Humanized chimeric bovine antibodies and methods of use
WO2022237974A1 (en) 2021-05-12 2022-11-17 Ecole Polytechnique Federale De Lausanne (Epfl) Krab-containing zinc finger protein and cancer
BR112023023951A2 (pt) 2021-05-28 2024-01-30 De Shaw Res Llc Compostos espiroindolinona como bloqueadores de canais shaker kv1.3 de potássio
CN115404240A (zh) 2021-05-28 2022-11-29 上海环码生物医药有限公司 制备环形rna的构建体、方法及其用途
WO2022261115A1 (en) 2021-06-07 2022-12-15 Yale University Peptide nucleic acids for spatiotemporal control of crispr-cas binding
JP2024522196A (ja) 2021-06-09 2024-06-11 ザ スクリプス リサーチ インスティテュート 長時間作用型デュアルｇｉｐ／ｇｌｐ－１ペプチドコンジュゲートおよび使用方法
WO2022271955A1 (en) 2021-06-23 2022-12-29 Musc Foundation For Research Development Novel targeted shrna nanoparticles for cancer therapy
EP4392455A4 (en) 2021-08-25 2025-08-20 Ibio Inc ANTI-CD-25 ANTIBODIES
EP4405392A1 (en) 2021-09-24 2024-07-31 Janssen Biotech, Inc. Proteins comprising cd20 binding domains, and uses thereof
AU2022383068A1 (en) 2021-11-08 2024-05-02 Orna Therapeutics, Inc. Lipid nanoparticle compositions for delivering circular polynucleotides
IL312811A (en) 2021-11-16 2024-07-01 Shanghai Argo Biopharmaceutical Co Ltd Composition and method for inhibiting angiotensinogen (agt) protein expression
CA3235672A1 (en) 2021-11-29 2023-06-01 Shanghai Argo Biopharmaceutical Co., Ltd. Compositions and methods for inhibiting expression of hepatitis b virus (hbv) protein
IL313726A (en) 2021-12-23 2024-08-01 Univ Massachusetts Medical treatment of fragile X-linked disorder
TW202345865A (zh) 2022-01-24 2023-12-01 大陸商上海舶望製藥有限公司 抑制LPA(Apo(a))蛋白表達的組合物和方法
TW202400647A (zh) 2022-04-29 2024-01-01 美商普瑞諾生物科技公司 用於治療嗜酸性球驅動之疾病及病症的方法及組成物
US20250320519A1 (en) 2022-05-30 2025-10-16 Shanghai Circode Biomed Co., Ltd. Synthetic circular rna compositions and methods of use thereof
US12297285B2 (en) 2022-06-24 2025-05-13 Orna Therapeutics, Inc. Circular RNA encoding chimeric antigen receptors targeting BCMA
WO2024039376A1 (en) 2022-08-18 2024-02-22 Elanco Us Inc. Method for improving growth performance in feedlot cattle
WO2024094526A1 (en) 2022-11-02 2024-05-10 Ecole Polytechnique Federale De Lausanne (Epfl) 6-diazo-5-oxo-l-norleucine prodrugs
WO2024102762A1 (en) 2022-11-08 2024-05-16 Orna Therapeutics, Inc. Lipids and lipid nanoparticle compositions for delivering polynucleotides
WO2024102730A1 (en) 2022-11-08 2024-05-16 Orna Therapeutics, Inc. Lipids and nanoparticle compositions for delivering polynucleotides
WO2024112515A1 (en) 2022-11-21 2024-05-30 Northeastern University Click chemistry ligand
CN120225676A (zh) 2022-12-02 2025-06-27 上海舶望制药有限公司 双环脱碱基核酸类似物以及由它们制备的寡聚化合物
EP4634390A2 (en) 2022-12-15 2025-10-22 Orna Therapeutics, Inc. Circular rna compositions and methods
WO2024205657A2 (en) 2023-03-29 2024-10-03 Orna Therapeutics, Inc. Lipids and lipid nanoparticle compositions for delivering polynucleotides
TW202444908A (zh) 2023-04-06 2024-11-16 大陸商上海舶望製藥有限公司 ５＇－膦酸酯修飾的核苷類似物及其製備的寡核苷酸
WO2024233308A2 (en) 2023-05-05 2024-11-14 Orna Therapeutics, Inc. Circular rna compositions and methods
WO2024263649A1 (en) 2023-06-19 2024-12-26 Yale University Methods and compositions for enrichment and sequencing of expansion-specific rna transcripts
WO2025007148A1 (en) 2023-06-30 2025-01-02 Orna Therapeutics, Inc. Polymer lipid nanoparticle compositions for delivering circular polynucleotides
WO2025021993A1 (en) 2023-07-27 2025-01-30 Omnilinx Therapeutics Ag Endocytic and scavenger receptor-targeting chimeric proteins and uses thereof
TW202521512A (zh) 2023-07-31 2025-06-01 美商美國禮來大藥廠 Kv1.3鉀shaker通道阻斷劑之固體形式及其使用方法
WO2025049690A1 (en) 2023-08-29 2025-03-06 Orna Therapeutics, Inc. Circular polyethylene glycol lipids
WO2025059689A1 (en) 2023-09-16 2025-03-20 University Of Massachusetts Compositions and methods for promoting the generation of pharyngeal foregut endoderm and its derivatives
EP4537907A1 (en) 2023-10-10 2025-04-16 Enthera S.r.l. Cd248 inhibitors and uses thereof
WO2025117969A1 (en) 2023-12-01 2025-06-05 Orna Therapeutics, Inc. Process for manufacturing lipid nanoparticles
WO2025240947A1 (en) 2024-05-17 2025-11-20 University Of Massachusetts Therapeutic treatment for fragile x-associated disorder
WO2025247961A1 (en) 2024-05-31 2025-12-04 Centre Hospitalier Universitaire Vaudois (C.H.U.V.) Lpa-lpar signaling as a therapeutic target or diagnostic tool for brain diseases
WO2025257176A1 (en) 2024-06-13 2025-12-18 Ideogen A.G. Combination therapy for treating cancer such as lymphoma
WO2025257173A1 (en) 2024-06-13 2025-12-18 Ideogen A.G. Combination therapy for treating cancer such as lymphoma
WO2025257171A1 (en) 2024-06-13 2025-12-18 Ideogen A.G. Combination therapy for treating cancer such as lymphoma

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2736682A (en) * 1954-10-11 1956-02-28 Victor M Hermelin Method of making a prolonged action medicinal tablet
US3039933A (en) * 1957-10-07 1962-06-19 Premo Pharmaceutical Lab Inc Ethyl cellulose-polyethylene glycol tablet matrix
US3093831A (en) * 1959-10-22 1963-06-18 Jordan Gerhard Paul Wilhelm Artificial gland
BE636865A (enExample) * 1962-08-31
US3518340A (en) * 1968-04-15 1970-06-30 Dow Corning Method of forming silicone rubber drug carriers
US3577512A (en) * 1968-10-11 1971-05-04 Nat Patent Dev Corp Sustained release tablets
US3598122A (en) * 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3630200A (en) * 1969-06-09 1971-12-28 Alza Corp Ocular insert

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT395815B (de) * 1981-06-29 1993-03-25 Alza Corp Therapeutisches abgabesystem zur verabreichung eines wirkstoffes durch die haut
EP0144486A3 (en) * 1983-04-27 1986-05-14 Lohmann Gmbh & Co Kg Controlled-release drugsystem and process for preparing it

Also Published As

Publication number Publication date
DE2135533A1 (de) 1973-02-01
DE2135533C3 (de) 1981-02-12
FR2143564A1 (en) 1973-02-09
FR2143564B1 (enExample) 1974-04-05
US3854480A (en) 1974-12-17
DE2135533B2 (de) 1980-06-04

Similar Documents

Publication Publication Date Title
FR2143564B1 (enExample)
AU2270770A (enExample)
CS148810B1 (enExample)
AU465452B2 (enExample)
CS153545B2 (enExample)
AU5461069A (enExample)
AU2355770A (enExample)
AU470301B1 (enExample)
AU5113869A (enExample)
AU410358B2 (enExample)
AU414607B2 (enExample)
AU442380B2 (enExample)
AU470661B1 (enExample)
AT308690B (enExample)
CS153549B2 (enExample)
AU4923469A (enExample)
AU5077469A (enExample)
AU1036070A (enExample)
AU4949169A (enExample)
AU5598769A (enExample)
AR203167Q (enExample)
AU5397469A (enExample)
AU5228269A (enExample)
AU5133369A (enExample)
CS149992B1 (enExample)

Legal Events

Date Code Title Description
PL Patent ceased
PL Patent ceased